 The study found that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to chemotherapy. These subtypes were identified using genomic expression profiling of fresh frozen tumor samples from three different cohorts. Additionally, the study identified two immunohistochemical markers, GATA3 and KRT5-6, which are sufficient to accurately distinguish between the two subtypes. This finding suggests that the molecular subtypes of bladder cancer may have distinct clinical behaviors and sensitivities to chemotherapy, and that a simple two-marker immunohistochemical classifier can be used for prognostic and therapeutic stratification. This article was offered by the Polkamar-Dedinia, Miao Zhang, Li Zhang, and others.